telbivudine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
uridine derivatives used as antiviral agents and as antineoplastics 4220 3424-98-4

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • sebivo
  • telbivudine
  • beta-L-Thymidine
  • epavudine
  • L-Thymidine
A thymidine derivative and antiviral agent that inhibits DNA synthesis by HEPATITIS B VIRUS and is used for the treatment of CHRONIC HEPATITIS B.
  • Molecular weight: 242.23
  • Formula: C10H14N2O5
  • CLOGP: -1.38
  • LIPINSKI: 0
  • HAC: 7
  • HDO: 3
  • TPSA: 99.10
  • ALOGS: -0.56
  • ROTB: 2
  • Status: OFM
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.60 g O

ADMET properties:

PropertyValueReference
BA (Bioavailability) 68 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
S (Water solubility) 66.80 mg/mL Bocci G, Oprea TI, Benet LZ
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Bocci G, Oprea TI, Benet LZ
fu (Fraction unbound in plasma) 1 % Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K

Approvals:

DateAgencyCompanyOrphan
April 24, 2007 EMA
Oct. 25, 2006 FDA NOVARTIS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug resistance 97.63 91.29 20 145 22913 63465944

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Blood creatine phosphokinase increased 152.55 72.89 50 665 44807 34911409
Drug resistance 117.27 72.89 36 679 25891 34930325
Hepatitis B DNA increased 92.70 72.89 15 700 550 34955666
Myalgia 85.43 72.89 39 676 84071 34872145

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Blood creatine phosphokinase increased 203.28 62.78 57 694 66033 79677604
Drug resistance 118.42 62.78 34 717 42179 79701458
Hepatitis B DNA increased 106.46 62.78 16 735 799 79742838
Viral mutation identified 93.95 62.78 18 733 3840 79739797
Myalgia 91.15 62.78 41 710 185600 79558037
Pathogen resistance 90.50 62.78 22 729 14320 79729317

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC J05AF11 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIVIRALS FOR SYSTEMIC USE
DIRECT ACTING ANTIVIRALS
Nucleoside and nucleotide reverse transcriptase inhibitors
FDA MoA N0000009947 Nucleoside Reverse Transcriptase Inhibitors
FDA EXT N0000175459 Nucleoside Analog
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000998 Antiviral Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D019384 Nucleic Acid Synthesis Inhibitors
FDA EPC N0000175656 Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor
CHEBI has role CHEBI:36044 antiviral drugs
CHEBI has role CHEBI:59897 reverse transcriptase inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Chronic type B viral hepatitis indication 61977001
Myositis contraindication 26889001 DOID:633
Kidney disease contraindication 90708001 DOID:557
Lactic acidosis contraindication 91273001 DOID:3650
Disorder of muscle contraindication 129565002 DOID:423
Steatosis of liver contraindication 197321007
Peripheral nerve disease contraindication 302226006
Breastfeeding (mother) contraindication 413712001




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.46 acidic
pKa2 13.02 acidic
pKa3 13.7 acidic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
600MG TYZEKA NOVARTIS N022011 Oct. 25, 2006 DISCN TABLET ORAL 7589079 Sept. 11, 2023 TREATMENT OF CHRONIC HEPATITIS B IN ADULT PATIENTS
600MG TYZEKA NOVARTIS N022011 Oct. 25, 2006 DISCN TABLET ORAL 7858594 Sept. 11, 2023 TREATMENT OF CHRONIC HEPATITIS B IN ADULT PATIENTS
100MG/5ML TYZEKA NOVARTIS N022154 April 28, 2009 DISCN SOLUTION ORAL 7858594 Sept. 11, 2023 TREATMENT OF CHRONIC HEPATITIS B IN ADULT PATIENTS

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Protein P Polyprotein INHIBITOR EC50 5.89 DRUG LABEL DRUG LABEL
Capsid protein Unclassified EC50 6.09 CHEMBL

External reference:

IDSource
4025782 VUID
N0000179779 NUI
D06675 KEGG_DRUG
4025782 VANDF
C1453933 UMLSCUI
CHEBI:63624 CHEBI
LLT PDB_CHEM_ID
CHEMBL374731 ChEMBL_ID
D000077712 MESH_DESCRIPTOR_UI
DB01265 DRUGBANK_ID
8296 INN_ID
2OC4HKD3SF UNII
159269 PUBCHEM_CID
474128 RXNORM
22372 MMSL
d05912 MMSL
011809 NDDF
424071004 SNOMEDCT_US
425347005 SNOMEDCT_US

Pharmaceutical products:

None